375 related articles for article (PubMed ID: 8822949)
1. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
Pierson BA; Miller JS
Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
[TBL] [Abstract][Full Text] [Related]
2. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture.
Cervantes F; Pierson BA; McGlave PB; Verfaillie CM; Miller JS
Blood; 1996 Mar; 87(6):2476-85. PubMed ID: 8630414
[TBL] [Abstract][Full Text] [Related]
3. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets.
Silla LM; Pincus SM; Locker JD; Glover J; Elder EM; Donnenberg AD; Nardi NB; Bryant J; Ball ED; Whiteside TL
Br J Haematol; 1996 May; 93(2):375-85. PubMed ID: 8639431
[TBL] [Abstract][Full Text] [Related]
4. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
[TBL] [Abstract][Full Text] [Related]
5. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
6. Human natural killer cell expansion is regulated by thrombospondin-mediated activation of transforming growth factor-beta 1 and independent accessory cell-derived contact and soluble factors.
Pierson BA; Gupta K; Hu WS; Miller JS
Blood; 1996 Jan; 87(1):180-9. PubMed ID: 8547640
[TBL] [Abstract][Full Text] [Related]
7. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
Verfaillie C; Kay N; Miller W; McGlave P
Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
[TBL] [Abstract][Full Text] [Related]
8. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia.
Hauch M; Gazzola MV; Small T; Bordignon C; Barnett L; Cunningham I; Castro-Malaspinia H; O'Reilly RJ; Keever CA
Blood; 1990 Jun; 75(11):2250-62. PubMed ID: 2189508
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
10. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity.
Verfaillie C; Miller W; Kay N; McGlave P
Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805
[TBL] [Abstract][Full Text] [Related]
11. Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia.
Yao D; Xu L; Liu L; Zeng X; Zhong J; Lai J; Zheng R; Jin Z; Chen S; Zha X; Huang X; Lu Y
Biomed Res Int; 2020; 2020():9531549. PubMed ID: 33102599
[TBL] [Abstract][Full Text] [Related]
12. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
13. Imbalance between CD56+bright and CD56+dim natural killer cell subsets in the liver of patients with recurrent hepatitis C after liver transplantation.
Yamagiwa S; Sato Y; Ichida T; Setsu T; Tominaga K; Kamimura H; Tsuchiya A; Takamura M; Matsuda Y; Aoyagi Y
Biomed Res; 2014; 35(3):177-84. PubMed ID: 24942856
[TBL] [Abstract][Full Text] [Related]
14. The role of autologous natural killer cells in chronic myelogenous leukemia.
Pierson BA; Miller JS
Leuk Lymphoma; 1997 Nov; 27(5-6):387-99. PubMed ID: 9477121
[TBL] [Abstract][Full Text] [Related]
15. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.
Krijgsman D; de Vries NL; Skovbo A; Andersen MN; Swets M; Bastiaannet E; Vahrmeijer AL; van de Velde CJH; Heemskerk MHM; Hokland M; Kuppen PJK
Cancer Immunol Immunother; 2019 Jun; 68(6):1011-1024. PubMed ID: 31053876
[TBL] [Abstract][Full Text] [Related]
16. Killer Ig-like receptor (KIR) genotype predicts the capacity of human KIR-positive CD56dim NK cells to respond to pathogen-associated signals.
Korbel DS; Norman PJ; Newman KC; Horowitz A; Gendzekhadze K; Parham P; Riley EM
J Immunol; 2009 May; 182(10):6426-34. PubMed ID: 19414796
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells.
Chang WC; Fujimiya Y; Casteel N; Pattengale P
Int J Cancer; 1989 Apr; 43(4):591-7. PubMed ID: 2522912
[TBL] [Abstract][Full Text] [Related]
18. An early increase of CD56
Iniesta P; Revilla N; Chen-Liang TH; Hurtado AM; Vicente V; Heras I; Jerez A; Lozano ML
Transfusion; 2018 Dec; 58(12):2924-2932. PubMed ID: 30260547
[TBL] [Abstract][Full Text] [Related]
19. Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells.
Fujimiya Y; Chang WC; Bakke A; Horwitz D; Pattengale PK
Cancer Immunol Immunother; 1987; 24(3):213-20. PubMed ID: 3496152
[TBL] [Abstract][Full Text] [Related]
20. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
